Bristol-Myers Squibb (BMS) is a global pharmaceutical company headquartered in New York, USA, with significant research and development operations in oncology, immunology, and neuroscience. Following its 2019 merger with Celgene and subsequent acquisitions, BMS has become one of the world's largest pharmaceutical companies.
Gosuranemab (formerly BIIB092) is an anti-tau monoclonal antibody that was originally developed by Biogen and later associated with Bristol-Myers Squibb through the company's pipeline. It targets the N-terminal region of tau protein.
Gosuranemab is a humanized IgG1 monoclonal antibody that binds to the N-terminal region of tau protein. The rationale for N-terminal targeting was:
However, gosuranemab represents the first generation of anti-tau antibodies, which have since been largely abandoned due to lack of clinical efficacy despite strong biomarker engagement.
Phase 2 Results
Gosuranemab was evaluated in Phase 2 clinical trials for both Alzheimer's disease and progressive supranuclear palsy:
Key Findings:
| Compound | Indication | Mechanism | Phase | Status |
|---|---|---|---|---|
| Gosuranemab | AD/PSP | Anti-tau N-terminal antibody | Phase 2 | Discontinued |
The failure of gosuranemab and similar N-terminal targeting antibodies (tilavonemab, zagotenemab) has informed the next generation of tau immunotherapy:
Bristol-Myers Squibb has a significant neuroscience portfolio through various partnerships and internal programs:
| Attribute | Detail |
|---|---|
| Headquarters | New York, New York, USA |
| Founded | 1887 (Bristol-Myers), 1888 (Squibb) |
| CEO | Chris Boerner |
| Market Cap | ~$100 billion |
| Employees | ~50,000 |